Related Experiment Videos
ROS-responsive "smart" polymeric conjugate: Synthesis, characterization and proof-of-concept study
Natalia Oddone1, Francesca Pederzoli2, Jason T Duskey1
1Nanotech Lab TeFarTI Group, University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy.
International Journal of Pharmaceutics
|September 4, 2019
Summary
New smart prodrugs utilize a ROS-cleavable Thioketal (TK) linker for targeted drug delivery. This technology enables selective drug release in response to oxidative stress, showing promise for cancer treatment.
Area of Science:
- Biomedical Engineering
- Drug Delivery Systems
- Nanotechnology
Background:
- Prodrugs are inactive drug precursors that release active compounds under specific conditions.
- Stimuli-responsive prodrugs offer enhanced therapeutic efficacy and reduced side effects.
- Oxidative stress is implicated in various diseases, including cancer, making it a target for drug delivery.
Purpose of the Study:
- To investigate the ROS-responsiveness of prodrugs incorporating the Thioketal (TK) moiety.
- To demonstrate the selective release of a payload (Cy5) in response to reactive oxygen species (ROS).
- To evaluate the potential of TK-based prodrugs for targeted cancer therapy.
Main Methods:
- Synthesis of a ROS-responsive conjugate: mPEG-TK-Cy5.
- Comparison with a non-ROS-responsive control conjugate: mPEG-Cy5.
- In vitro studies using ROS-simulated conditions and glioblastoma cells.
Main Results:
- The mPEG-TK-Cy5 conjugate demonstrated selective release of Cy5 in the presence of ROS.
- The control conjugate mPEG-Cy5 did not show significant Cy5 release under similar conditions.
- Successful in vitro drug release was observed in glioblastoma cells.
Conclusions:
- Thioketal (TK) technology is effective for designing ROS-responsive prodrugs.
- This approach facilitates targeted drug delivery in conditions characterized by oxidative stress.
- TK-based prodrugs represent a promising strategy for cancer treatment and potentially other diseases.